The role of m6A and m6Am RNA modifications in the pathogenesis of diabetes mellitus

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F23%3A00573796" target="_blank" >RIV/67985823:_____/23:00573796 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11310/23:10467043 RIV/00216208:11110/23:10467043

Result on the web

<a href="https://doi.org/10.3389/fendo.2023.1223583" target="_blank" >https://doi.org/10.3389/fendo.2023.1223583</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fendo.2023.1223583" target="_blank" >10.3389/fendo.2023.1223583</a>

Result language

angličtina

Original language name

The role of m6A and m6Am RNA modifications in the pathogenesis of diabetes mellitus

Original language description

The rapidly developing research field of epitranscriptomics has recently emerged into the spotlight of researchers due to its vast regulatory effects on gene expression and thereby cellular physiology and pathophysiology. N6-methyladenosine (m6A) and N6,2’-O-dimethyladenosine (m6Am) are among the most prevalent and well-characterized modified nucleosides in eukaryotic RNA. Both of these modifications are dynamically regulated by a complex set of epitranscriptomic regulators called writers, readers, and erasers. Altered levels of m6A and also several regulatory proteins were already associated with diabetic tissues. This review summarizes the current knowledge and gaps about m6A and m6Am modifications and their respective regulators in the pathophysiology of diabetes mellitus. It focuses mainly on the more prevalent type 2 diabetes mellitus (T2DM) and its treatment by metformin, the first-line antidiabetic agent. A better understanding of epitranscriptomic modifications in this highly prevalent disease deserves further investigation and might reveal clinically relevant discoveries in the future.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30105 - Physiology (including cytology)

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in Endocrinology

ISSN

1664-2392

e-ISSN

1664-2392

Volume of the periodical

14

Issue of the periodical within the volume

July

Country of publishing house

CH - SWITZERLAND

Number of pages

11

Pages from-to

1223583

UT code for WoS article

001030189600001

EID of the result in the Scopus database

2-s2.0-85165287408